banner
 
bar

program

slides

  test

syllabus
bar
 
 

The Evolving Therapeutic Landscape
for Multiple Sclerosis

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period June 24, 2010 through June 24, 2012 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

3.5 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the management of multiple sclerosis.

Release Date:

June 24, 2010

Expiration Date:

June 24, 2012

Intended Audience:

This complimentary CME educational activity is designed for all neurology-focused physicians, nurses, NPs, academicians, pharmacists, researchers, investigators, and program directors managing, referring, and/or consulting on patients with neurological disorders, with a focus on multiple sclerosis. We welcome neurology-focused clinicians with a medical and educational needs in the fields of general neurology, multiple sclerosis, internal medicine, and other providers that are part of the multidisciplinary team caring for patients with these and related conditions.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Teva NeuroscienceSupported by an independent
educational grant from
Teva Neuroscience, Inc

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of University of Massachusetts Medical School and CMEducation Resources, LLC. University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

University of Massachusetts Medical School designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Bruce A. Cree, MD, PhD, MCR – Program Chairman
Assistant Professor of Neurology
Department of Neurology
University of California
San Francisco Multiple Sclerosis Center
San Francisco, California

Consultant: Biogen Idec, Teva Neuroscience, EMD Serono
Grant/Research Support: Biogen Idec



Mark J. Tullman, MD
Assistant Professor of Neurology
Director, Multiple Sclerosis Clinical Care Center
The Neurological Institute of New York
Columbia University Medical Center
New York, New York

Consultant: Biogen Idec, Accorda Therapeutics, Serono, Novartis, Sanofi-Aventis, Neuroscience, Vaccinex
Speaker’s Bureau: Pfizer, EMD Serono
Grant/Research Support: Accorda Therapeutics, Actelion



Guy J. Buckle, MD, MPH
Director of MS Clinical Care Partners Multiple Sclerosis Center
Brigham and Women’s Hospital
Assistant Professor of Neurology
Harvard Medical School
Boston, Massachusetts

Nothing to disclose


Rohit Bakshi, MD, MPH
Director, Laboratory for Neuroimaging Research
Partners Multiple Sclerosis Center
Associate Professor of Neurology & Radiology
Brigham & Women’s Hospital, Harvard Medical School
Boston, Massachusetts

Grant/Research Support: Teva Neuroscience, Biogen Idec, EMD, Serono

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewers Denise Leary and Richard Aghababian, MD have nothing to disclose.

Educational Objectives:

Participants will be able to:

  • Better understand the date, expert analysis, and evidence supporting the foundation role of immunomodulation therapy (IMT) for long-term efficacy, safety, neuronal preservation, and disability mitigation in MS
  • Better able, in the clinical setting, to balance efficacy benefits against safety risks to achieve long-term efficacy with IMT
  • Become more clinically skilled at applying evidence and conclusions from long-term follow-up trials with IMT to the front lines of MS practice
  • Be better able to apply first-line therapy with immune-modulating agents (IMTs) to specific patient subgroups with MS
  • Be better able to understand the efficacy and safety issues associated with immunosuppressive agents for MS, with a focus on patient selection, monitoring, risks for infection, and mechanisms of action
  • Become more clinically proficient, based on clinical trial data, at optimizing long-term functional and financial outcomes in RRMS with immunomodulation therapy
  • Be better able to assess the enduring efficacy, reduction of disability metrics (EDSS, MSSS, and MSFC), and maintenance of Quality of Life (QOL) Measures associated with MS therapies
  • Better able to utilize neuroimaging in multiple sclerosis and better understand its utility for monitoring disease progression, timing of intervention, and choice of neurotherapeutic strategies
  • Better able to evaluate clinical results and monitoring effects of immune-modulation therapies with current and evolving scanning techniques

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer:

Copyright © 2011 Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides

  test

syllabus
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2011 Resources, LLC All rights reserved.

 
6

 

Key Program Topics Include:

ACT
alemtuzumab
Avonex
Axonal
Azathioprine
Behçet
BENEFIT
betaseron
BEYOND
Brain Atrophy
brain stem
CD4+ T
cerebellum,
spinal cord
cerebral cortex
CHAMPIONS
CHAMPS/ETOMS

Copaxone
Corticosteroids
Cyclophosphamide
daclizumab
Demyelination
DMD
EDSS
EVIDENCE
Glatiramer acetate
HIV
HTLV-1
Human IgG4
IFN b-1a
IFN b-1b
Immunosuppression
Laquinimod

 

INCOMIN
Interferon
Lesions
Lyme disease
Methotrexate
Mitoxantrone
MRI
Multiple Sclerosis
relapsing-remitting MS
Mycophenolate mofetil
Natalizumab
neuritic transection
neurodegenerative
Neurosyphilis
NMSS
Novantrone
optic nerves
periventricular
PML
PRECISE
PRISMS
Rebif
REGARD
rituximab
RRMS
Sarcoidosis
Selective adhesion molecule inhibitor
Sjögren syndrome
Statins
Tysabri
white matter